These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32661000)

  • 1. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation Solution.
    Bhavnani SM; Hammel JP; Lakota EA; Safir MC; VanScoy BD; Nagira Y; Rubino CM; Sato N; Koresawa T; Kondo K; Ambrose PG
    Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32661000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
    Bader JC; Lakota EA; Dale GE; Sader HS; Rex JH; Ambrose PG; Bhavnani SM
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetic Analyses for Arbekacin after Administration of ME1100 Inhalation Solution.
    Lakota EA; Sato N; Koresawa T; Kondo K; Bhavnani SM; Ambrose PG; Rubino CM
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
    Bhavnani SM; Trang M; Griffith DC; Lomovskaya O; Hammel JP; Loutit JS; Cammarata SK; Dudley MN; Ambrose PG; Rubino CM
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0213021. PubMed ID: 36374023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and pharmacokinetics of ME1100, a novel optimized formulation of arbekacin for inhalation, compared with amikacin in a murine model of ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
    Kaku N; Morinaga Y; Takeda K; Kosai K; Uno N; Hasegawa H; Miyazaki T; Izumikawa K; Mukae H; Yanagihara K
    J Antimicrob Chemother; 2017 Apr; 72(4):1123-1128. PubMed ID: 27999047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae.
    Bhavnani SM; Hammel JP; Lakota EA; Trang M; Bader JC; Bulik CC; VanScoy BD; Rubino CM; Huband MD; Friedrich L; Steenbergen JN; Ambrose PG
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0221321. PubMed ID: 36946741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia.
    Bhavnani SM; Zhang L; Hammel JP; Rubino CM; Bader JC; Sader HS; Gelone SP; Wicha WW; Ambrose PG
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii35-iii41. PubMed ID: 30949705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric Approaches.
    Lepak AJ; Trang M; Hammel JP; Sader HS; Bhavnani SM; VanScoy BD; Pogue JM; Ambrose PG; Andes DR;
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0145222. PubMed ID: 36946729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
    Bulik CC; Okusanya ÓO; Lakota EA; Forrest A; Bhavnani SM; Hoover JL; Andes DR; Ambrose PG
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae.
    Lepak AJ; Zhao M; Liu Q; Wang P; Wang Y; Bader JC; Ambrose PG; Andes DR
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus.
    Sato R; Tanigawara Y; Kaku M; Aikawa N; Shimizu K
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3763-9. PubMed ID: 17065622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.
    Lepak AJ; Andes DR
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4764-9. PubMed ID: 27216072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia.
    Sader HS; Rhomberg PR; Farrell DJ; Jones RN
    Antimicrob Agents Chemother; 2015; 59(6):3263-70. PubMed ID: 25801559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).
    Noreddin AM; Marras TK; Sanders K; Chan CK; Hoban DJ; Zhanel GG
    Int J Antimicrob Agents; 2004 Nov; 24(5):479-84. PubMed ID: 15519481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients.
    Li L; Wu H; Chen Y; Yuan H; Wu J; Wu X; Zhang Y; Cao G; Guo B; Wu J; Zhao M; Zhang J
    Clin Ther; 2020 May; 42(5):818-829. PubMed ID: 32389326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin against Streptococcus pneumoniae Using Data from a Neutropenic Murine Lung Infection Model.
    Okusanya OO; Forrest A; Bhavnani SM; Fernandes P; Ambrose PG; Andes DR
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of arbekacin in different infectious disease settings and evaluation of dosing regimens.
    Hagihara M; Kato H; Hamada Y; Hirai J; Sakanashi D; Suematsu H; Nishiyama N; Koizumi Y; Yamagishi Y; Matsuura K; Mikamo H
    J Infect Chemother; 2016 Jul; 22(7):436-43. PubMed ID: 27260679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3935-41. PubMed ID: 14638504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.
    Hoover J; Lewandowski T; Straub RJ; Novick SJ; DeMarsh P; Aubart K; Rittenhouse S; Zalacain M
    Antimicrob Agents Chemother; 2016 Jan; 60(1):180-9. PubMed ID: 26482300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
    Gao W; Patel YT; Zhang Z; Johnson MG; Fiedler-Kelly J; Bruno CJ; Rhee EG; Anda C; Feng HP
    J Clin Pharmacol; 2023 Mar; 63(3):352-357. PubMed ID: 36201105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.